PT-141 Peptide Research
PT-141, also known as bremelanotide, is one of the few peptides in this database with a modern FDA-approved drug analog and a clear clinical identity.
sexual-health peptide
Approved Drug Level
research maturity
Overview
PT-141, also known as bremelanotide, is one of the few peptides in this database with a modern FDA-approved drug analog and a clear clinical identity. It is best understood through the formal bremelanotide literature in sexual-desire disorders.
Primary goals
Comparisons
Related stacks
Libido Stack
Mechanism
It acts as a melanocortin receptor agonist, influencing central pathways involved in sexual desire and arousal rather than acting through vasodilation like PDE5 inhibitors. That central mechanism differentiates it from drugs like sildenafil.
Clinical interest
Clinical interest focuses on hypoactive sexual desire, sexual-arousal signaling, and libido biology. Compared with many gray-market peptides, its clinical story is unusually concrete.
Research summary
The literature includes randomized trials, phase 3 analyses, and pharmacology reviews. The evidence supports modest but real efficacy in the appropriate clinical context, especially compared with many peptides that never reach this level of development.
Safety considerations
It still requires careful framing around adverse effects, blood-pressure considerations, nausea, and indication-specific use. Approval does not make it a universal sexual-performance solution.
Key information
Research stage
Approved Drug Level
Evidence rating
High
Search intent
informational
Last review
Mar 13, 2026
Featured studies
(
7
)
Frequently asked questions
What is PT-141?
PT-141 is the peptide known clinically as bremelanotide, a melanocortin receptor agonist used in sexual-desire disorders rather than as a vascular erectile drug.
How is PT-141 different from Viagra?
Viagra works mainly by enhancing nitric-oxide-mediated vasodilation, while PT-141 acts centrally through melanocortin pathways involved in desire and arousal.